FDA PMA For VASCADE™ Vascular Closure System

Cardiva Medical, Inc. has gained an FDA Premarket Approval (PMA) for the VASCADE Vascular Closure System (VCS). Clinical data demonstrated that the VASCADE VCS is clinically and statistically superior in both safety and efficacy compared to manual compression for patients undergoing percutaneous procedures through the femoral artery.



Cardiva Medical, Inc. Announces U.S. FDA Approval for VASCADE™ Vascular Closure System (via PR Newswire)

SUNNYVALE, Calif., Feb. 6, 2013 /PRNewswire/ — Cardiva Medical, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for the VASCADE Vascular Closure System (VCS). Clinical data from a prospective, multi-center, randomized 420 patient trial demonstrated…


published: February 7, 2013 in: Approval/Clearance, Cardio, Vascular

Most read

Latest

^